Gyre Therapeutics Stock Price To Book
| GYRE Stock | 7.02 0.37 5.56% |
Fundamental analysis of Gyre Therapeutics allows traders to better anticipate movements in Gyre Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
The current year's Price To Book Ratio is expected to grow to 17.51. Gyre | Price To Book | Build AI portfolio with Gyre Stock |
Gyre Therapeutics Company Price To Book Analysis
Gyre Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Gyre Therapeutics Price To Book | 8.85 X |
Most of Gyre Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gyre Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gyre Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Gyre Therapeutics is extremely important. It helps to project a fair market value of Gyre Stock properly, considering its historical fundamentals such as Price To Book. Since Gyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Gyre Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Gyre Therapeutics has a Price To Book of 8.8497 times. This is 65.54% lower than that of the Biotechnology sector and 46.52% higher than that of the Health Care industry. The price to book for all United States stocks is 6.94% higher than that of the company.
Gyre Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gyre Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gyre Therapeutics could also be used in its relative valuation, which is a method of valuing Gyre Therapeutics by comparing valuation metrics of similar companies.Gyre Therapeutics is currently under evaluation in price to book category among its peers.
Gyre Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Gyre Therapeutics from analyzing Gyre Therapeutics' financial statements. These drivers represent accounts that assess Gyre Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gyre Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.8B | 418.2M | 610.1M | 1.6B | 1.0B | 978.2M | |
| Enterprise Value | 1.8B | 376.3M | 588.4M | 1.5B | 1.0B | 968.5M |
Gyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Gyre Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0518 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 574.56 M | ||||
| Shares Outstanding | 90.66 M | ||||
| Shares Owned By Insiders | 89.85 % | ||||
| Shares Owned By Institutions | 3.01 % | ||||
| Number Of Shares Shorted | 1.81 M | ||||
| Price To Book | 8.85 X | ||||
| Price To Sales | 5.99 X | ||||
| Revenue | 105.76 M | ||||
| Gross Profit | 96.84 M | ||||
| EBITDA | 17.82 M | ||||
| Net Income | 17.9 M | ||||
| Total Debt | 1.6 M | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (3.64 M) | ||||
| Short Ratio | 9.88 X | ||||
| Earnings Per Share | 0.02 X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 579 | ||||
| Market Capitalization | 602.87 M | ||||
| Total Asset | 125.41 M | ||||
| Retained Earnings | (73.45 M) | ||||
| Working Capital | 45.27 M | ||||
| Net Asset | 125.41 M |
About Gyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out Gyre Therapeutics Piotroski F Score and Gyre Therapeutics Altman Z Score analysis. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth (0.19) | Return On Assets |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.